sGC Inhibitors
1 drugsAbout sGC
Soluble guanylate cyclase (sGC) is an enzyme crucial in cardiovascular physiology, regulating vasodilation, inflammation, and fibrosis. Activated by nitric oxide (NO), sGC produces cyclic GMP (cGMP), a second messenger mediating these effects.
sGC is a therapeutic target due to its role in vasodilation. Currently, there is no genetic evidence data available linking sGC to specific diseases.
sGC is targeted by one FDA-approved drug, VERQUVO (Merck), a small molecule used in cardiovascular medicine. VERQUVO was first approved in 2021.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Left Ventricular Systolic Dysfunction with only 1 trials.
Top Drugs
Merck is the only company with an approved sGC-targeting drug.
High market concentration suggests significant entry barriers; focus on novel mechanisms or indications.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets sGC, using small molecule modality.
Explore alternative modalities like biologics to differentiate from existing small molecule approaches.
Clinical Trials 43 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 18 | 14 | 0 | 4 | 100% |
| Phase 2 | 12 | 5 | 0 | 7 | 100% |
| Phase 3 | 4 | 3 | 0 | 1 | 100% |
| Phase 4 | 9 | 3 | 1 | 5 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2021 - 2021)
The first and only sGC-targeting drug, VERQUVO, was approved in 2021.
Recent approval indicates a growing interest in sGC modulation, but market saturation is low.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 33 clinical trials targeting sGC.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities